Entera Bio Ltd. (NASDAQ:ENTX) CEO Miranda Jayne Toledano Acquires 30,000 Shares
Entera Bio Ltd. (NASDAQ:ENTX) CEO Miranda Jayne Toledano Acquires 30,000 Shares
Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) CEO Miranda Jayne Toledano bought 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 4th. The stock was purchased at an average price of $1.01 per share, with a total value of $30,300.00. Following the completion of the purchase, the chief executive officer now owns 86,800 shares in the company, valued at $87,668. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Entera Bio Ltd.（納斯達克股票代碼：ENTX — 獲取評級）首席執行官米蘭達·傑恩·託萊達諾在4月4日星期二進行的一筆交易中購買了該公司3萬股股票。該股票以每股1.01美元的平均價格購買，總價值爲30,300.00美元。收購完成後，首席執行官現在擁有該公司86,800股股票，價值87,668美元。該交易已在向美國證券交易委員會提交的文件中披露，該文件可在以下網址查閱 美國證券交易委員會網站。
Entera Bio Stock Down 6.4 %
Entera Bio 股票下跌6.4％
Shares of ENTX stock opened at $0.86 on Friday. Entera Bio Ltd. has a 1-year low of $0.47 and a 1-year high of $3.00. The stock has a 50 day simple moving average of $1.01 and a 200-day simple moving average of $0.88.
週五，ENTX股票開盤價爲0.86美元。Entera Bio Ltd.的1年低點爲0.47美元，爲1年高點3.00美元。該股的50天簡單移動平均線爲1.01美元，200天簡單移動平均線爲0.88美元。
Analyst Upgrades and Downgrades
分析師升級和降級
Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Tuesday.
另外，HC Wainwright在週二的一份研究報告中重申了 “買入” 評級，並對Entera Bio的股票發佈了10.00美元的目標股價。
Hedge Funds Weigh In On Entera Bio
對沖基金對 Entera Bio 施加壓力
Large investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. acquired a new position in Entera Bio during the first quarter worth $29,000. Millennium Management LLC raised its position in Entera Bio by 358.5% during the fourth quarter. Millennium Management LLC now owns 46,000 shares of the company's stock worth $34,000 after acquiring an additional 35,968 shares during the period. Finally, Renaissance Technologies LLC raised its position in Entera Bio by 555.4% during the fourth quarter. Renaissance Technologies LLC now owns 139,600 shares of the company's stock worth $102,000 after acquiring an additional 118,300 shares during the period. 20.12% of the stock is currently owned by institutional investors and hedge funds.
大型投資者最近增加了或減少了他們在該股的股份。PNC金融服務集團公司在第一季度收購了Entera Bio的新職位，價值29,000美元。千禧管理有限責任公司在第四季度將其在Entera Bio的頭寸提高了358.5％。千禧管理有限責任公司在此期間又收購了35,968股股票後，現在擁有該公司46,000股股票，價值34,000美元。最後，文藝復興科技有限責任公司在第四季度將其在Entera Bio的頭寸提高了555.4％。Renaissance Technologies LLC在此期間又收購了118,300股股票後，現在擁有該公司價值10.2萬美元的139,600股股票。該股票的20.12％目前由機構投資者和對沖基金持有。
About Entera Bio
關於 Entera Bio
(Get Rating)
（獲取評級）
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
Entera Bio Ltd. 是一家臨牀階段的生物製藥公司，從事口服大分子療法的開發和商業化。它的產品線包括PTH、GLP-E和HGH，該公司成立於2009年9月30日，總部位於以色列耶路撒冷。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
- What Factors Will Drive S&P 500 Performance This Year?
- 2 Beautiful Investments In A Growing Industry
- Hypercharge Networks: Up Triple Digits, But What's The Big Deal?
- 3 Reasons Why Apple's 30% Rally Has Legs
- 3 Reasons to Pick First Citizens Instead of First Republic Bank
- 免費獲取 StockNews.com 關於 Entera Bio (ENTX) 的研究報告的副本
- 哪些因素將推動標準普爾500指數今年的表現？
- 成長型行業的2項漂亮投資
- Hypercharge Networks：上漲了三位數，但有甚麼大不了的？
- 蘋果30％的漲勢有長足的3個原因
- 選擇原住民而不是第一共和國銀行的3個理由
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Entera Bio Daily 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Entera Bio及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。